Study provides more data for ovarian cancer risk prediction

This article originally appeared here.
Share this content:
Study Provides More Data for Ovarian Cancer Risk Prediction
Study Provides More Data for Ovarian Cancer Risk Prediction

(HealthDay News) -- Among asymptomatic women, high-risk categories for predicting ovarian cancer risk can be identified using CA125, transvaginal ultrasonography, or both, providing guidance for clinical decisions regarding need for surgery in these women, according to research published in the January issue of Obstetrics & Gynecology.

Edward E. Partridge, M.D., of the University of Alabama at Birmingham, and colleagues estimated the risk of ovarian malignancy using data from a cohort of 3,224 asymptomatic postmenopausal women from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. The participants had an abnormal transvaginal ultrasound scan or CA125 level at an initial (T0) or subsequent annual (T1) screening.

At T0, the researchers identified two high-risk categories: negative transvaginal ultrasound scan and CA125 of 70 or more (positive predictive value [PPV], 15.9 percent); and positive for CA125 and transvaginal ultrasound (PPV, 25.0 percent). The high-risk T0 criteria had a sensitivity of 60 percent, a specificity of 96.2 percent, a PPV of 19.7 percent, and a negative predictive value (NPV) of 99.3 percent. Three high-risk categories were identified at the T1 screening: change in CA125 of 45 or more with negative ultrasound (PPV, 29.0 percent); negative CA125 and increase of 6 cm or more in size of cyst (PPV, 13.3 percent); and positive for both tests (PPV, 42.9 percent). High-risk T1 criteria had a sensitivity of 85.3 percent, a specificity of 95.6 percent, a PPV of 29.6 percent, and an NPV of 99.7 percent.

"The large number of women in this study, the four-year complete follow-up, and small number of invasive cancers in the low-risk categories provide guidance for clinical decisions regarding need for surgery in these women," the authors write.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs